Breaking new ground with antibody-drug conjugates in myeloma

capital inflows, and strong patient demand. 4 The market is too large to ignore; however, its growing domestic CAR T-cell industry and opaque regulatory processes make global launch sequencing far less predictable for multinational firms.These features mean China can shape commercial strategies in ways that differ from both high-income and other middle-income settings.